Investment Thesis
GT Biopharma is a pre-revenue pharmaceutical company with zero commercial sales and mounting operational losses (-$2.8M), coupled with negative operating cash flow (-$2.5M) that limits runway to approximately 3-4 quarters at current burn rates. The company destroys shareholder value with negative ROE (-37.4%) and ROA (-34.9%), with only a strong liquidity position (4.14x current ratio) as a buffer.
Strengths
- Strong liquidity with 4.14x current ratio and $8.9M cash equivalents
- No long-term debt and minimal leverage (0.00x Debt/Equity) reduces financial risk
- Positive stockholders' equity of $7.6M provides equity cushion
Risks
- Zero revenue - no commercial product generating sales
- Negative cash flow from operations at $2.5M annually with approximately 3-4 quarter runway
- Severely negative profitability metrics (ROE -37.4%, ROA -34.9%) indicate value destruction
- No insider buying activity suggests lack of confidence from management
- Pre-revenue biotech status with unproven commercialization capability
Key Metrics to Watch
- Revenue generation and commercial product launch timeline
- Quarterly cash burn rate and cash runway adequacy
- R&D spending efficiency and pipeline clinical trial progress
- Insider trading activity and capital raise announcements
Financial Metrics
Revenue
0.0
Net Income
-2.8M
EPS (Diluted)
$-0.11
Free Cash Flow
-2.5M
Total Assets
8.1M
Cash
8.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-37.4%
ROA
-34.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.14x
Quick Ratio
4.14x
Debt/Equity
0.00x
Debt/Assets
16.3%
Interest Coverage
-13.37x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:26:19.546922 |
Data as of: 2026-03-31 |
Powered by Claude AI